ZIMMER BIOMET HOLDINGS, INC. (ZBH): what the price requires
At today's price, ZIMMER BIOMET HOLDINGS, INC. (ZBH) is priced for +1.2% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.
Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/ZBH
Headline
| Field | Value |
|---|---|
| Ticker | ZBH |
| Company | ZIMMER BIOMET HOLDINGS, INC. |
| Current price | $93.70/sh |
| Composition | Knees 40% / Hips 25% / S.E.T 26% / Technology & Data, Bone Cement and Surgical 8% |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | whole-company |
| Operating margin needed | 7.5% |
| Operating margin today | 16.3% |
| Margin compression implied | -8.8pp |
| Implied growth | 1.2% |
| Multiple paid | 19x operating income |
The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.
Solve inputs: computed at a 7.3% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~7.7pp.
Reconcile: at the x-ray's 9.3% required return this reads ~15.3%/yr; the models below use their own rates.
How unusual the bet is: within-range
| Reference | Value |
|---|---|
| vs own history | -0.29σ |
| cohort percentile (of 112 peers) | 41 |
| implied end-window share | 0% |
Valuation X-Ray
The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 2.84x | 5 | expensive |
| Earnings | 2.32x | 4 | expensive |
| Relative | 0.62x | 3 | justifies |
| Growth | 0.73x | 3 | justifies |
Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.7%); the inversion above states its own rate.
Per-Model Detail (n=15)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $212.12 | 0.44x | yes | FCF base $1.6B, growth 9% (input: historical growth), terminal g 4.0%, WACC 7.7%, 6yr projection |
| DCF Exit Multiple | Growth | $127.65 | 0.73x | yes | Exit EV/EBITDA: 9.1x / 11.1x / 13.1x (bear / base = today's held flat / bull), 6yr |
| Relative Valuation | Relative | $126.51 | 0.74x | yes | P/E 24x (static sector reference · 2026-04), scenarios: 20.0x / 24.0x / 28.0x (bear / base = reference held flat / bull), EV/EBITDA 16x |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $42.03 | 2.23x | yes | BV/sh $64.73, ROE (TTM) 6.0%, ke 9.3% |
| Two-Stage Excess Return | Asset | $32.98 | 2.84x | yes | 5yr excess ROE then converge to ke=9.3% |
| Discounted Future Market Cap | Growth | $79.83 | 1.17x | yes | Rev $8.4B, growth 9% (input: historical growth; tapered), Terminal P/S: 1.8x / 2.2x / 2.5x (bear / base = today's held flat / bull, cap 8x) |
| Growth-Adjusted P/E | Relative | — | — | no | — |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | $18.71 | 5.01x | yes | Normalized EBIT (5y avg op income, one-time charges added back) $1.05B × (1−21%) / WACC 7.7% → EPV (no growth) |
| Residual Income | Asset | $31.81 | 2.95x | yes | BV $64.73 + 5yr PV of (ROE (TTM) 6.0% − Kₑ 9.3%) × BV; BV grows 3.9%/yr |
| Graham Number | Asset | $74.98 | 1.25x | yes | √(22.5 × EPS $3.86 × BVPS $64.73) — Graham's conservative floor |
| EV/EBITDA Relative | Relative | $151.01 | 0.62x | yes | EBITDA $2.29B × sector EV/EBITDA 16.0x |
| FCF Yield | Earnings | $44.48 | 2.11x | yes | FCF $1457.5M / Kₑ 9.3% — zero-growth perpetuity |
| SBC-Adj FCF Yield | Earnings | $39.25 | 2.39x | yes | SBC-adj FCF $1.36B (FCF $1.46B − SBC $0.09B) capitalized at Kₑ |
| Ben Graham Formula | Earnings | $3.24 | 28.92x | yes | EPS $3.86 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median) |
| ROIC-Justified P/B | Asset | $12.55 | 7.47x | yes | BV $64.73 × (ROIC 1.5% / WACC 7.7%) |
| P/Sales Sector | Relative | $171.79 | 0.55x | yes | Revenue $8.41B × sector P/S 4.0x |
| PEG Fair Value | Relative | — | — | no | — |
| Earnings Yield | Earnings | $41.73 | 2.25x | yes | EPS $3.86 / required return 9.3% (Rf 4.3% + ERP 5.0%) |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net debt | $7.0b |
| Net debt / NOPAT (after-tax) | 6.77x |
| Net debt / operating income (pre-tax) | 5.35x |
| Share count CAGR (buyback) | -1.7% |
| Burning cash | no |
Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.
Bullet Takeaways
- Zimmer Biomet is a leading maker of knee and hip implants plus surgical and robotics products, competing directly with the largest names in orthopedics, which its 10-K lists as "Johnson & Johnson MedTech... Stryker Corporation and Smith & Nephew plc."
- The defining risk is execution against a soft setup: 2026 guidance is for organic revenue growth of just 1% to 3%, with up to 100 basis points of pricing erosion expected and a U.S. sales-force transition underway, while net debt sits near six times trailing operating income.
- What to watch is whether innovation reaccelerates growth: the company completed its acquisition of Monogram Technologies to build toward autonomous orthopedic robotics, with commercialization on Zimmer Biomet implants expected by early 2027.
Bull Case
What the market is pricing into Zimmer Biomet is essentially no growth, and that is a low bar for a business with a genuine demographic tailwind. At about 18 times operating income, the inversion implies roughly flat operating-profit growth, a slight decline even, sustained over five years, and the stock sits in the lower half of its peer multiple range. For a company that makes the artificial knees and hips an aging population increasingly needs, pricing in stagnation is a meaningful amount of pessimism. Joint replacement is one of the more durable demand stories in healthcare: the procedures are elective but not optional for the patients who need them, and the volume grows with age demographics regardless of the economic cycle.
The competitive position is real and the portfolio is broadening. The 10-K names Zimmer Biomet against "Johnson & Johnson MedTech... Stryker Corporation and Smith & Nephew plc," the short list of companies that matter in large-joint orthopedics, and Zimmer holds a leading share in knees and hips. Recent results show the franchise is not stagnant: full-year 2025 net sales grew 7.2% to $8.232 billion, with organic constant-currency growth of 3.9%, and the fourth quarter ran faster at 10.9% reported. The company is also pushing into the part of orthopedics that is growing fastest, robotics, completing the acquisition of Monogram Technologies to add a CT-based, AI-navigated robotic knee system that received FDA clearance and is expected to commercialize on Zimmer implants by early 2027.
The value case rests on the gap between a no-growth price and a low-single-digit-growth business that returns cash. Even on its conservative 2026 guidance of 1% to 3% organic growth, the company expects to keep growing, and it buys back stock, with the share count drifting lower. The relative-multiple and growth-DCF lenses both support the current price, and analysts see meaningful upside, with the consensus target around $98 and individual firms reaching to $105 and $118 on positive surgeon feedback about the product pipeline. The bull case does not need a growth surprise; it needs the business to grow at all, which the price barely assumes, and for the robotics investment to reaccelerate the trajectory over time.
Bear Case
Look at how the growth is being manufactured and you find the bear case. Full-year reported sales grew 7.2%, but organic constant-currency growth was only 3.9%, and the 2026 organic guidance steps down to just 1% to 3%. The gap between reported and organic growth is acquisitions doing the work that the underlying business is not, and the company's history of buying growth shows up on the balance sheet: net debt of about $7 billion sits at nearly six times trailing operating income, heavy leverage for a medtech business. The 10-K acknowledges the risk that integration can disrupt "business operations due to integration matters related to mergers and acquisitions" and strain relationships with customers, suppliers, and lenders. A company leaning on M&A to supplement thin organic growth, while carrying significant debt, has less room for error than its franchise quality suggests.
The pricing environment is structurally against it. The customers are increasingly hospitals and group purchasing organizations that, as the 10-K puts it, "have formed group purchasing organizations in an effort to contain costs" and negotiate hard on price. Zimmer Biomet itself expects up to 100 basis points of pricing erosion in 2026 as price increases moderate in Europe and decline in Asia Pacific. In a business where volume growth is modest and tied to demographics, persistent price deflation is a direct headwind to revenue and margin, and it is largely outside the company's control because the buyers have the leverage.
The near-term execution risk is self-inflicted and concrete. Management is overhauling its U.S. sales force, and the soft 2026 guidance explicitly reflects the disruption from that transition alongside new-product adoption cycles and international softness. A sales-force reorganization in a relationship-driven business, where surgeons and hospitals rely on consistent rep coverage, can cost real revenue if it goes poorly. The valuation captures the tension: the asset-based and earnings-power lenses call the price expensive, while only the relative-multiple and growth-DCF lenses justify it. The bear reading is that the low multiple is appropriate, not a bargain, because a levered, M&A-dependent business facing pricing erosion and a sales-force disruption deserves to trade in the lower half of its peer range until it proves organic growth can reaccelerate.
Valuation
At the current price the market pays about 18 times company-wide operating income, which inverts to roughly flat operating-profit growth, a touch negative, held over five years. That near-term pace is within what the company has recently delivered on an organic basis, and the read is labeled within range, with the stock sitting in the lower half of its peer multiple range. In plain terms, the price is paying for a no-growth-to-low-growth outcome, which is a forgiving assumption for a market-leading orthopedics franchise but a fair one given the soft organic trajectory.
The valuation families split cleanly. The relative-multiple and growth-DCF lenses support the price, while the asset-based and earnings-power lenses call it expensive. The reconciliation is that against medtech peers Zimmer Biomet screens cheap, but on its own asset base and current earnings power, the price looks full. Which lens is right depends on whether the franchise can convert its demographic tailwind and robotics investment into reaccelerating organic growth, or whether pricing erosion and competition hold it near the low-single-digit pace the methods that call it expensive are extrapolating.
Solvency is the constraint that deserves weight here. Net debt of about $7 billion at nearly six times trailing operating income is meaningful leverage, accumulated through acquisitions, and it limits financial flexibility and adds interest cost. The company still generates enough cash to service the debt and buy back stock, so this is not a distress situation, but it does mean the downside in a weak organic year is amplified, and it raises the bar for the next acquisition to earn its keep. The price assumes the business at least holds steady; the leverage is what makes a stumble more costly than the modest multiple would suggest.
Catalysts
The fourth-quarter and full-year 2025 results, reported in February 2026, beat expectations on the headline but revealed a softer core. Fourth-quarter net sales rose 10.9% to $2.244 billion, 5.4% organic, and full-year sales grew 7.2% to $8.232 billion, 3.9% organic. The spread between reported and organic growth reflects the contribution of acquisitions, which is the lens through which to read the company's growth profile.
The 2026 guidance is the catalyst that reset expectations downward. Management guided organic constant-currency revenue growth to just 1% to 3%, citing risks from the U.S. sales-force transition, new-product adoption cycles, and international performance, and flagged up to 100 basis points of pricing erosion as price increases moderate in Europe and decline in Asia Pacific. The sales-force overhaul is the execution variable to watch, since it can swing near-term revenue in either direction.
The innovation pipeline is the offsetting forward catalyst. The completed acquisition of Monogram Technologies adds a CT-based, AI-navigated semi-autonomous knee robotics platform that received FDA clearance and is expected to commercialize on Zimmer Biomet implants by early 2027. Analysts hold a mixed view, with a hold consensus and an average target near $98 but individual targets reaching to $105 and $118 on positive surgeon feedback. The events most likely to move the thesis are the organic-growth prints against the 1% to 3% guidance, the smoothness of the sales-force transition, and early commercial traction for the robotics platform.
Peer Cohorts (Per Segment, With Filing Citations)
Core business (reported)
- SYK (STRYKER CORP)
- (no filing in the citation store)
- MDT (Medtronic plc)
- (no filing in the citation store)
- STE (STERIS plc)
- (no filing in the citation store)
- MMSI (MERIT MEDICAL SYSTEMS INC)
- (no filing in the citation store)
- BDX (BECTON DICKINSON & CO)
- (no filing in the citation store)
- ITGR (INTEGER HOLDINGS CORPORATION)
- (no filing in the citation store)
- SOLV (SOLVENTUM CORPORATION)
- (no filing in the citation store)
- ICUI (ICU MEDICAL INC/DE)
- (no filing in the citation store)
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.
Sources
Zimmer Biomet Monogram acquisition disclosure, 2025 · Zimmer Biomet Q4 2025 results, February 2026 · analyst notes via Stifel and Bernstein, 2026 · Zimmer Biomet 2026 guidance